Prostate Cancer Screening Restricted to High-Risk Men as Experts Warn of Potential Harm from Widespread Testing

Prostate Cancer: Health authorities have recommended that routine prostate cancer screening should only be offered to a small group of men at very high genetic risk, arguing that the potential harms of widespread testing currently outweigh the benefits.

The recommendation, issued by the United Kingdom’s National Screening Committee (NSC), marks the culmination of an extensive review into whether population-wide prostate cancer screening should be introduced. While screening can save lives by detecting cancers early, experts concluded that current testing methods also carry significant risks, including overdiagnosis and unnecessary treatment that can permanently affect a man’s quality of life.

Under the new guidance, only men who carry a BRCA2 genetic mutation and have a family history of breast, ovarian, pancreatic, or prostate cancer should be invited for routine screening. The committee estimates that this recommendation will apply to only a few thousand men annually.

Why the Recommendation Matters

Prostate cancer is the most common cancer affecting men and remains a major public health concern. The disease develops in the prostate gland, a small organ located below the bladder that contributes to the production of seminal fluid and influences urinary function.

According to the review, prostate cancer claims approximately 12,000 lives each year in the UK, prompting calls from campaigners and health advocates for broader screening programmes.

However, the committee found that the benefits of widespread screening remain limited when weighed against the risks associated with current diagnostic and treatment approaches.

How Prostate Cancer Screening Works

Screening typically begins with a Prostate-Specific Antigen (PSA) blood test, which measures levels of a protein produced by the prostate gland. Elevated PSA levels may indicate cancer but can also result from non-cancerous conditions such as prostate enlargement or infection.

Men with abnormal PSA results are often referred for further investigations, including MRI scans and, in some cases, biopsies.

While these tests can identify cancer at an early stage, experts note that they cannot always distinguish between aggressive cancers that require treatment and slow-growing cancers that may never become life-threatening.

The Hidden Risks of Screening

One of the most significant concerns highlighted by the review is overdiagnosis—the detection of cancers that would never have caused symptoms or shortened a person’s life.

The committee found that for every 1,000 men screened in their 50s, approximately two deaths from prostate cancer could be prevented over a 15-year period. However, the same screening programme would also identify around 20 men with cancers that would never require treatment.

Some prostate cancers progress so slowly that a man could live well into old age without ever experiencing complications from the disease.

Despite this, a cancer diagnosis often leads to anxiety, repeated medical appointments, and difficult treatment decisions.

Of the 20 men unnecessarily diagnosed, the review estimated that around 12 would go on to receive treatment they did not actually need.

Treatment Can Have Life-Changing Consequences

Current prostate cancer treatments can have serious side effects.

Procedures such as surgery and radiotherapy may damage surrounding tissues and nerves, leading to:

• Erectile dysfunction
• Urinary incontinence
• Bladder control problems
• Long-term sexual health challenges
• Reduced quality of life

Professor Sir Mike Richards, Chair of the National Screening Committee, noted that one of the major limitations of current medical knowledge is the inability to reliably determine which prostate cancers will become dangerous and which will remain harmless.

As a result, some men undergo invasive treatment for cancers that may never have threatened their health.

Who Should Not Be Screened?

Following its review, the committee concluded that routine screening should not currently be offered to:

• All men in the general population
• Black men as a separate screening group
• Men with a family history of prostate cancer alone

The recommendation regarding Black men has attracted particular attention because research consistently shows they face approximately double the risk of developing prostate cancer compared to other groups.

However, experts say there is still insufficient evidence to determine whether prostate cancers occurring in Black men are biologically more aggressive. This uncertainty influenced the committee’s decision not to recommend a separate screening programme at this stage.

Why BRCA2 Mutation Carriers Are Different

The committee identified one group where the benefits of screening clearly outweighed the risks.

Men who carry a BRCA2 gene mutation and have a relevant family history of cancer face substantially higher risks of developing aggressive prostate cancer.

BRCA2 plays an important role in repairing damaged DNA. Mutations in this gene increase susceptibility to several cancers and are associated with more aggressive disease patterns.

For these individuals, the committee recommends PSA screening every two years between the ages of 45 and 61.

Future Evidence Could Change the Decision

Despite its cautious stance, the National Screening Committee emphasized that its recommendations are not permanent.

Researchers are currently investigating:

• Improved PSA testing methods
• Advanced MRI techniques
• Artificial intelligence tools for cancer detection
• Better ways to identify aggressive cancers
• The ongoing Transform Trial examining prostate cancer risks in Black men

Experts believe these developments could eventually support broader screening programmes if evidence demonstrates that benefits outweigh harms.

Professor Richards expressed hope that future scientific advances would make wider screening possible but stressed that robust evidence remains essential before such a programme can be introduced.

Mixed Reactions from Campaigners

The recommendations have generated strong reactions from advocacy groups and public figures.

Campaigners including former Prime Ministers, sports personalities, and celebrities have argued that wider screening could save thousands of lives. Among the most prominent voices is Olympic cycling legend Chris Hoy, who is living with terminal prostate cancer and has campaigned for greater awareness and earlier detection.

However, health experts supporting the committee’s position argue that introducing a national screening programme without sufficient evidence could expose many healthy men to unnecessary medical interventions and lifelong complications.

The Final Decision Lies with Governments

Although the National Screening Committee has issued its recommendations, implementation remains a political decision.

Health ministers in England, Scotland, Wales, and Northern Ireland will now consider the advice before determining whether and how to adopt the proposed screening programme.

For now, the committee’s message is clear: while prostate cancer remains a significant health threat, current evidence supports targeted screening only for a small group of genetically high-risk men rather than the wider population.

Source: BBC

Also read: Kidney disease: The silent health threat Ghana cannot ignore